ES8504173A1 - Un procedimiento para la preparacion de diarilpirazinas o triazinas - Google Patents

Un procedimiento para la preparacion de diarilpirazinas o triazinas

Info

Publication number
ES8504173A1
ES8504173A1 ES526297A ES526297A ES8504173A1 ES 8504173 A1 ES8504173 A1 ES 8504173A1 ES 526297 A ES526297 A ES 526297A ES 526297 A ES526297 A ES 526297A ES 8504173 A1 ES8504173 A1 ES 8504173A1
Authority
ES
Spain
Prior art keywords
triazine
pyrazine derivatives
pyrazine
derivatives
diarylpyrazines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES526297A
Other languages
English (en)
Other versions
ES526297A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of ES8504173A1 publication Critical patent/ES8504173A1/es
Publication of ES526297A0 publication Critical patent/ES526297A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PROCEDIMIENTO PARA LA PREPARACION DE DIARILPIRAZINAS O TRIAZINAS, DE FORMULA GENERAL (I), EN LA QUE R1 Y R2 SON ALQUILO O CLORO; X ES CH O N; Q ES OXIGENO; Y A ES UN GRUPO AMINO, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES.CONSISTE EN HACER REACCIONAR UN COMPUESTO DE FORMULA GENERAL (I), EN LA QUE A ES UN GRUPO: -O-FENILO, CON AMONIACO O CON UNA AMINA DE FORMULA: HNRR.DE APLICACION COMO ACTIVANTES DE LA UNION DEL ACIDO GAMMA-AMINOBUTIRICO Y DE LA BENZODIAZEPINA EN EL SISTEMA NERVIOSO CENTRAL DE LOS MAMIFEROS.
ES526297A 1982-03-05 1983-10-06 Un procedimiento para la preparacion de diarilpirazinas o triazinas Granted ES526297A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/354,982 US4513135A (en) 1982-03-05 1982-03-05 Diaryl-pyrazine derivatives affecting GABA binding

Publications (2)

Publication Number Publication Date
ES8504173A1 true ES8504173A1 (es) 1985-04-16
ES526297A0 ES526297A0 (es) 1985-04-16

Family

ID=23395746

Family Applications (2)

Application Number Title Priority Date Filing Date
ES520340A Granted ES520340A0 (es) 1982-03-05 1983-03-04 Un procedimiento para la preparacion de diarilpirazinas o triazinas.
ES526297A Granted ES526297A0 (es) 1982-03-05 1983-10-06 Un procedimiento para la preparacion de diarilpirazinas o triazinas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES520340A Granted ES520340A0 (es) 1982-03-05 1983-03-04 Un procedimiento para la preparacion de diarilpirazinas o triazinas.

Country Status (22)

Country Link
US (2) US4513135A (es)
EP (1) EP0088593B1 (es)
JP (1) JPS58162582A (es)
KR (1) KR860000847B1 (es)
AT (1) ATE27457T1 (es)
AU (1) AU547581B2 (es)
CA (1) CA1195327A (es)
DD (1) DD207716A5 (es)
DE (1) DE3371786D1 (es)
DK (1) DK97283A (es)
ES (2) ES520340A0 (es)
FI (1) FI830708L (es)
GB (1) GB2116179B (es)
GR (1) GR78459B (es)
HU (1) HU191368B (es)
IL (1) IL68002A (es)
NZ (1) NZ203428A (es)
PH (1) PH22535A (es)
PL (1) PL240871A1 (es)
PT (1) PT76312B (es)
RO (1) RO86320B (es)
ZA (1) ZA831387B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
JPH06501926A (ja) * 1990-08-06 1994-03-03 藤沢薬品工業株式会社 複素環式化合物
GB9420010D0 (en) * 1994-10-01 1994-11-16 Marck Sharp & Dohme Limited Nucleic acids
USRE41920E1 (en) 1996-07-24 2010-11-09 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
TWI316055B (es) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
KR100490893B1 (ko) * 2002-10-11 2005-05-23 (주) 비엔씨바이오팜 2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
MX2007009224A (es) * 2005-02-01 2008-03-13 Lake Erie Products Sujetador para evitar el trasroscado.
CA2606288A1 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) * 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PT2531492T (pt) 2010-02-05 2016-07-07 Heptares Therapeutics Ltd Derivados 1,2,4-triazina4-amina
GB201106829D0 (en) 2011-04-21 2011-06-01 Proximagen Ltd Heterocyclic compounds
TW201321353A (zh) * 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯／尿素衍生物
EP3484856B1 (en) * 2016-07-12 2023-11-15 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
US11339135B2 (en) 2016-11-30 2022-05-24 Mitsubishi Tanabe Pharma Corporation Method for producing triazine compound
BR112019014527A2 (pt) 2017-01-23 2020-02-27 Revolution Medicines, Inc. Compostos de piridina como inibidores de shp2 alostéricos
EP3571199A1 (en) 2017-01-23 2019-11-27 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
EP3678703A1 (en) 2017-09-07 2020-07-15 Revolution Medicines, Inc. Shp2 inhibitor compositions and methods for treating cancer
AU2018347516A1 (en) 2017-10-12 2020-05-07 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, C28-, and C-32-linked rapamycin analogs as MTOR inhibitors
EP3788050A1 (en) 2018-05-01 2021-03-10 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172889A (en) * 1965-03-09 Process for the separation of z-methyl-
US3294638A (en) * 1961-06-05 1966-12-27 Warner Lambert Pharmaceutical Method and compositions employing 2-alkyl-3-piperidinopyrazines
CH480795A (de) * 1967-03-01 1969-11-15 Sandoz Ag Mittel zur Beeinflussung des Pflanzenwachstums
US3948894A (en) * 1974-01-31 1976-04-06 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US3989831A (en) * 1974-01-31 1976-11-02 Eli Lilly And Company Topically-active anti-inflammatory 3-chloro-5,6-diaryl-1,2,4-triazines
US3979516A (en) * 1974-01-31 1976-09-07 Eli Lilly And Company Anti-inflammatory 3-amino-5,6-diaryl-1,2,4-triazines
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US4081542A (en) * 1975-04-21 1978-03-28 Merck & Co., Inc. Piperazinylpyrazines
GB1493998A (en) * 1975-06-03 1977-12-07 Beecham Group Ltd Propanolamine derivatives
US4008232A (en) * 1975-06-23 1977-02-15 Eli Lilly And Company 3-Amino-5,6-diaryl-1,2,4-triazines
US4082844A (en) * 1976-02-09 1978-04-04 Merck & Co., Inc. 6-chloro-2-(1-piperazinyl)pyrazine
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
US4190725A (en) * 1976-03-10 1980-02-26 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
NL7802514A (nl) * 1977-03-09 1978-09-12 Fabre Sa Pierre 5,6-diaryl-1,2,4-triazinederivaten en werkwijze ter bereiding van deze verbindingen.
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
CH633541A5 (en) * 1977-05-17 1982-12-15 Diamond Shamrock Corp Pharmacologically active substituted 1,2,4-triazines and medicaments containing these triazines
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines

Also Published As

Publication number Publication date
US4513135A (en) 1985-04-23
EP0088593A3 (en) 1984-05-23
DD207716A5 (de) 1984-03-14
NZ203428A (en) 1986-09-10
ES526297A0 (es) 1985-04-16
GR78459B (es) 1984-09-27
HU191368B (en) 1987-02-27
DE3371786D1 (en) 1987-07-02
IL68002A (en) 1986-09-30
ES8404346A1 (es) 1984-04-16
KR840004101A (ko) 1984-10-06
IL68002A0 (en) 1983-06-15
FI830708A0 (fi) 1983-03-02
EP0088593A2 (en) 1983-09-14
GB8305846D0 (en) 1983-04-07
AU547581B2 (en) 1985-10-24
PT76312B (en) 1986-02-04
PT76312A (en) 1983-04-01
GB2116179A (en) 1983-09-21
ES520340A0 (es) 1984-04-16
RO86320B (ro) 1985-03-31
PH22535A (en) 1988-10-17
US4585861A (en) 1986-04-29
ATE27457T1 (de) 1987-06-15
ZA831387B (en) 1984-10-31
JPS58162582A (ja) 1983-09-27
AU1202983A (en) 1983-09-08
PL240871A1 (en) 1984-06-18
DK97283D0 (da) 1983-02-28
GB2116179B (en) 1985-09-11
CA1195327A (en) 1985-10-15
DK97283A (da) 1983-09-06
FI830708L (fi) 1983-09-06
EP0088593B1 (en) 1987-05-27
KR860000847B1 (ko) 1986-07-09
RO86320A (ro) 1985-03-15

Similar Documents

Publication Publication Date Title
ES8504173A1 (es) Un procedimiento para la preparacion de diarilpirazinas o triazinas
ES8801546A1 (es) Un procedimiento para la preparacion de compuesto de 2,2-difluoronucleosidos.
AU1574483A (en) Bismaleimide triazine composition
SU1089968A1 (ru) Магнитореологическая суспензия
ES8507530A1 (es) Un procedimiento para la preparacion de aricoxicicloalcanolaminolaminoalquilen-aril-cetonas.
PL252065A1 (en) Method of obtaining 2,3,4,5-tetrahydro-1h-/1,4/diazepin /1,7-a/indoles
SU1115543A1 (ru) Маслоотделитель
SU1083739A1 (ru) Стокс-калибратор
SU1256381A1 (ru) Способ переработки редкоземельного концентрата
SU1090131A1 (ru) Акселерометр
SU1122635A1 (ru) Спеченный композиционный материал
RO87212B1 (ro) Derivati de p-fluorbenzamida
SU1195570A1 (ru) Багажник-палатка крыши автомобиля
SU1086938A1 (ru) Способ голографической согласованной фильтрации
SU1089873A1 (ru) Способ крепления деталей в электрическом поле
SU1114135A1 (ru) Манотрон
SU1120886A1 (ru) P-i-n-ДИОД
SU1217054A1 (ru) Стокс-модулятор
SU1154903A1 (ru) Способ получения 2-имино-3-фенил-6-фенацилиден-2,3,5,6 -тетрагидро-1,3,4-оксадиазин-5-онов
SU1111454A1 (ru) Способ получения (4,6-дизамещенный пиримидинил-2)тиофанийбромидов
SU1187376A1 (ru) Подвеска транспортного средства
SU1081967A2 (ru) Способ изготовления изделий из ячеистобетонной смеси
SU1018364A1 (ru) Способ получения п-толунитрила
SU1202352A2 (ru) Маслоотделитель
SU1107561A1 (ru) Способ очистки нефтяного остаточного сырья